Spectrum Of The Acquired Von Willebrand Syndrome In a Large Cohort Of Patients Diagnosed In a Single Institution

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 3607-3607 ◽  
Author(s):  
Ulrich Budde ◽  
Rita Dittmer ◽  
Hala El- Abd Müller ◽  
Hanna Schaeper ◽  
Sonja Schneppenheim

Abstract The first description of an apparently acquired form of von Willebrand disease dates back to 1968 in patients with systemic lupus erythematosus. To differentiate between the congenital and acquired forms, the term acquired von Willebrand syndrome (aVWS) is now accepted for these patients. It turned out that there are three predominant underlying diseases that lead to an aVWS in a subset or even in almost all affected patients. More than 9.000 samples reach our laboratory yearly for diagnosis, confirming or (sub-) classification of a possible VWD. In about 15% of these the diagnosis VWD can be confirmed and 30% of these patients suffer from an apparently acquired form. Here we describe our experience in diagnosing aVWS patients over more than 9 years (January 2004 – February 2013). The largest group are patients with cardiovascular diseases (483 = 40%). Since our first patients in 2005, the leading group are patients on non-pulsative left ventricular assist devices (LVADs) with still markedly increasing numbers. Aortic stenosis was the reason for aVWS in 139 patients, usually with less severe symptoms compared to patients on LVAD´s. In 67 patients the underlying diseases were congenital heart diseases. Miscellaneous cardiac defects were causative in 29 patients. Only nine patients were on an extracorporal membrane oxygenator. But all of them suffered from severe bleeding complications with a high mortality (five out of nine). The VWF:Ag was higher than normal (>160%) in all patient groups with the exception of the congenital cases. It seems to be influenced by the highth of the shear stress and the age of the patients. The mean VWF:CB was significantly lower compared to the VWF:Ag. Therefore the ratio between VWF:CB and VWF:Ag was low in all groups, but although our lower limit of a “normal” ratio is higher than usual (0.8), the sensitivity towards a loss of the large multimers is low with 60% in all groups. Thus without using multimer analysis as a first line diagnostic test, in a big part of patients with cardiovascular diseases, the aVWS will be overseen. The acquired VWS in patients with thrombocythemia and the pathophysiology was described in 1984 and 1986. In our 362 patients (30% of the whole group), the large multimers nearly always show an absolute or relative reduction. An aVWS with a phenotype similar to inherited VWD1 is rarely seen. Whether a given patient suffers from thromboembolism or bleedings is strongly dependent from the platelet count. Most patients investigated were not actively bleeding but were tested to confirm the diagnosis or to plan for the best treatment in case of surgery or trauma. The ratio between VWF:CB and VWF:Ag was low in these patients. The sensitivity towards a loss of the large multimers is somewhat better than in cardiovascular cases, but does not exceed 80%. Lymphoproliferative diseases as the underlying disorder associated with aVWS account for a significant portion of patients. We observed 243 patients between January 2004 and February 2013 (20% of the whole group). Typically in cases with a monoclonal IgG (201 patients) there is a relative decrease of the large multimers together with severely decreased or absent proteolytic bands. This is due to the preferential removal of the large multimers together with a too short time left for ADAMTS13 to cleave the molecule. In contrast, the majority of patients with monoclonal gammopathy of the IgM type had aVWS similar to inherited VWD type 1. They show an unmistakable multimeric pattern. This multimeric pattern can be explained by the giant VWF-IgM complexes which destroy the agarose during their passage through the gel and sometimes even leave holes. A brief inspection of the gels is thus sufficient for making correct diagnosis. In 114 patiens (9% of the whole group), the mechanism leading to an enhanced clearance (type 1) or destruction of the VWF structure (type 2) is unknown. Disclosures: No relevant conflicts of interest to declare.

Blood ◽  
2016 ◽  
Vol 127 (25) ◽  
pp. 3133-3141 ◽  
Author(s):  
Angelo Nascimbene ◽  
Sriram Neelamegham ◽  
O. H. Frazier ◽  
Joel L. Moake ◽  
Jing-fei Dong

Abstract Left ventricular assist devices (LVAD) provide cardiac support for patients with end-stage heart disease as either bridge or destination therapy, and have significantly improved the survival of these patients. Whereas earlier models were designed to mimic the human heart by producing a pulsatile flow in parallel with the patient’s heart, newer devices, which are smaller and more durable, provide continuous blood flow along an axial path using an internal rotor in the blood. However, device-related hemostatic complications remain common and have negatively affected patients’ recovery and quality of life. In most patients, the von Willebrand factor (VWF) rapidly loses large multimers and binds poorly to platelets and subendothelial collagen upon LVAD implantation, leading to the term acquired von Willebrand syndrome (AVWS). These changes in VWF structure and adhesive activity recover quickly upon LVAD explantation and are not observed in patients with heart transplant. The VWF defects are believed to be caused by excessive cleavage of large VWF multimers by the metalloprotease ADAMTS-13 in an LVAD-driven circulation. However, evidence that this mechanism could be the primary cause for the loss of large VWF multimers and LVAD-associated bleeding remains circumstantial. This review discusses changes in VWF reactivity found in patients on LVAD support. It specifically focuses on impacts of LVAD-related mechanical stress on VWF structural stability and adhesive reactivity in exploring multiple causes of AVWS and LVAD-associated hemostatic complications.


Hematology ◽  
2019 ◽  
Vol 2019 (1) ◽  
pp. 88-96
Author(s):  
F. W. G. Leebeek ◽  
R. Muslem

Abstract Chronic heart failure (HF) is a growing health problem, and it is associated with high morbidity and mortality. Left ventricular assist devices (LVADs) are nowadays an important treatment option for patients with end-stage HF not only as a bridging tool to heart transplantation but also, as a permanent therapy for end-stage HF (destination therapy). The use of LVAD is associated with a high risk for bleeding complications and thromboembolic events, including pump thrombosis and ischemic stroke. Bleeding is the most frequent complication, occurring in 30% to 60% of patients, both early and late after LVAD implantation. Although the design of LVADs has improved over time, bleeding complications are still the most common complication and occur very frequently. The introduction of an LVAD results in an altered hemostatic balance as a consequence of blood-pump interactions, changes in hemodynamics, acquired coagulation abnormalities, and the strict need for long-term anticoagulant treatment with oral anticoagulants and antiplatelet therapy. LVAD patients may experience an acquired coagulopathy, including platelet dysfunction and impaired von Willebrand factor activity, resulting in acquired von Willebrand syndrome. In this educational manuscript, the epidemiology, etiology, and pathophysiology of bleeding in patients with LVAD will be discussed. Because hematologist are frequently consulted in cases of bleeding problems in these individuals in a critical care setting, the observed type of bleeding complications and management strategies to treat bleeding are also reviewed.


2021 ◽  
Vol 7 ◽  
Author(s):  
Aniket S Rali ◽  
Ahmed M Salem ◽  
Melat Gebre ◽  
Taylor M Garies ◽  
Siva Taduru ◽  
...  

The initiation and management of anticoagulation is a fundamental practice for a wide variety of indications in cardiovascular critical care, including the management of patients with acute MI, stroke prevention in patients with AF or mechanical valves, as well as the prevention of device thrombosis and thromboembolic events with the use of mechanical circulatory support and ventricular assist devices. The frequent use of antiplatelet and anticoagulation therapy, in addition to the presence of concomitant conditions that may lead to a propensity to bleed, such as renal and liver dysfunction, present unique challenges. The use of viscoelastic haemostatic assays provides an additional tool allowing clinicians to strike a delicate balance of attaining adequate anticoagulation while minimising the risk of bleeding complications. In this review, the authors discuss the role that viscoelastic haemostatic assay plays in cardiac populations (including cardiac surgery, heart transplantation, extracorporeal membrane oxygenation, acute coronary syndrome and left ventricular assist devices), and identify areas in need of further study.


Sign in / Sign up

Export Citation Format

Share Document